老年弥漫性胶质瘤患者的特征与结局:关西中枢神经系统肿瘤分子诊断网络的多机构队列研究
该多机构回顾性队列纳入140例≥70岁原发弥漫性胶质瘤患者,中位年龄75岁,WHO IV级114例。IV级患者中位无进展生存期8.2个月、总生存期13.6个月。较高年龄(≥80岁)和TERT启动子突变与较短生存相关,切除及辅助放疗联合替莫唑胺被确定为良好预后的独立因素。
要点
- 140例≥70岁弥漫性胶质瘤患者中,WHO IV级114例,中位年龄75岁。
- IV级患者中位无进展生存期8.2个月,中位总生存期13.6个月。
- 切除及辅助放疗联合替莫唑胺为良好预后的独立因素。
核心结论
- 该社区为基础的研究揭示了真实世界老年胶质瘤患者的特征与结局,老年患者存在若干潜在不良预后因素,但切除后行放疗联合替莫唑胺可延长生存时间。
研究设计与样本
- 关西中枢神经系统肿瘤分子诊断网络的多机构回顾性队列研究,收集≥70岁原发弥漫性胶质瘤患者140例(WHO II级7例、III级19例、IV级114例),中位年龄75岁。
主要发现
- 67例(47.9%)术前卡氏功能状态评分≥80。
- 全部患者接受切除,全切除20.0%、次全切除14.3%、部分切除39.3%、活检26.4%。
- 96例(68.6%)接受辅助治疗,方案为放疗联合替莫唑胺;78例(75.0%)接受≥50 Gy放疗剂量。
- 68个肿瘤(48.6%)MGMT启动子甲基化,129个肿瘤(92.1%)IDH1/2为野生型,128个肿瘤中78个(60.9%)TERT启动子突变。
- IV级病例中位无进展生存期8.2个月、中位总生存期13.6个月;较高年龄(≥80岁)和TERT启动子突变与较短生存相关。
关键数值与推荐
- 切除和辅助放疗联合替莫唑胺被确定为良好预后的独立因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This study investigates the current state of clinical practice and molecular analysis for elderly patients with diffuse gliomas and aims to elucidate treatment outcomes and prognostic factors of patients with glioblastomas. METHODS: We collected elderly cases (≥ 70 years) diagnosed with primary diffuse gliomas and enrolled in Kansai Molecular Diagnosis Network for CNS Tumors. Clinical and pathological characteristics were analyzed retrospectively. Various factors were evaluated in univariate and multivariate models to examine their effects on overall survival. RESULTS: Included in the study were 140 elderly patients (WHO grade II: 7, III: 19, IV: 114), median age was 75 years. Sixty-seven patients (47.9%) had preoperative Karnofsky Performance Status score of ≥ 80. All patients underwent resection (gross-total: 20.0%, subtotal: 14.3%, partial: 39.3%, biopsy: 26.4%). Ninety-six of the patients (68.6%) received adjuvant treatment consisting of radiotherapy (RT) with temozolomide (TMZ). Seventy-eight of the patients (75.0%) received radiation dose of ≥ 50 Gy. MGMT promoter was methylated in 68 tumors (48.6%), IDH1/2 was wild-type in 129 tumors (92.1%), and TERT promoter was mutated in 78 of 128 tumors (60.9%). Median progression-free and overall survival of grade IV cases was 8.2 and 13.6 months, respectively. Higher age (≥ 80 years) and TERT promoter mutated were associated with shorter survival. Resection and adjuvant RT + TMZ were identified as independent factors for good prognosis. CONCLUSIONS: This community-based study reveals characteristics and outcomes of elderly glioma patients in a real-world setting. Elderly patients have several potential factors for poor prognosis, but resection followed by RT + TMZ could lengthen duration of survival.
引用
- Sasaki T, Fukai J, Kodama Y, et al. Characteristics and outcomes of elderly patients with diffuse gliomas: a multi-institutional cohort study by Kansai Molecular Diagnosis Network for CNS Tumors. J Neurooncol. 2018. PMID: 30076584. doi:10.1007/s11060-018-2957-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。